Evidence map›Paper›PMID 28959121›Full record

ArticleBiomarker insights2017

Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation.

Philip E Silkoff, Dave Singh, J Mark FitzGerald, Andreas Eich, Andrea Ludwig-Sengpiel, Geoffrey C Chupp, Vibeke Backer, Celeste Porsbjerg, Pierre-Olivier Girodet, Mark T Dransfield and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker insights, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Philip E SilkoffImmunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Dave SinghMedicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, UK.
J Mark FitzGeraldCentre for Heart and Lung Health, The Lung Centre, Vancouver General Hospital, Vancouver, BC, Canada.
Andreas EichIKF Pneumologie Frankfurt, Institut für klinische Forschung Pneumologie, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany.
Andrea Ludwig-SengpielKLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany.
Geoffrey C ChuppPulmonary Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Vibeke BackerRespiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.
Celeste PorsbjergRespiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark.
Pierre-Olivier GirodetCentre de Recherche Cardio-Thoracique de Bordeaux, Université de Bordeaux, Bordeaux, France.
Mark T DransfieldDivision of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Frederic BaribaudImmunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Vedrana S SusulicImmunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Matthew J LozaImmunology, Janssen Research & Development, LLC, Spring House, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleChronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and development of novel therapeutics requires an understanding of pathophysiologic phenotypes.

objectivesThe purpose of the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study was to correlate clinical features and biomarkers with molecular characteristics in a well-profiled COPD cohort.

methodsA total of 67 COPD subjects (forced expiratory volume in the first second of expiration [FEV MEASUREMENTS AND MAIN

resultsThe impact of inhaled corticosteroids (ICSs), and to a lesser extent current smoking, was more associated with symptom control, exacerbation rates, and clinical biomarkers, than severity by FEV

conclusionsCompared with COPD severity by FEV

Indexed as

COPDpersonalizedphenotypesprofilingseverity

Identifiers

PMID28959121
PMCPMC5593220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.